Alliance News2024-04-18T13:05:37-04:00

The first multicenter, randomized, controlled trial of home telemonitoring for Japanese patients with heart failure: home telemonitoring study for patients with heart failure (HOMES-HF)

The first multicenter, randomized, controlled trial of home telemonitoring for Japanese patients with heart failure: home telemonitoring study for patients with heart failure (HOMES-HF)

Abstract
Home telemonitoring is becoming more important to home medical care for patients with heart failure. Since there are no data on home telemonitoring for Japanese patients with heart failure, we investigated its effect on cardiovascular outcomes. The HOMES-HF study was the first multicenter, open-label, randomized, controlled trial (RCT) to elucidate the effectiveness of home telemonitoring of physiological data, such as body weight, blood pressure, and pulse rate, for Japanese patients with heart failure (UMIN Clinical Trials Registry 000006839). The primary end-point was a composite of all-cause death or rehospitalization due to worsening heart failure. We analyzed 181 recently hospitalized patients with heart failure who were randomly assigned to a telemonitoring group (n = 90) or a usual care group (n = 91). The mean follow-up period was 15 (range 0-31) months. There was no statistically significant difference in the primary end-point between groups [hazard ratio (HR), 0.95; 95% confidence interval (CI), 0.548-1.648; p = 0.572]. Home telemonitoring for Japanese patients with heart failure was feasible; however, beneficial effects in addition to those of usual care were not demonstrated. Further investigation of more patients with severe heart failure, participation of home medical care providers, and use of a more integrated home telemonitoring system emphasizing communication as well as monitoring of symptoms and physiological data are required.

August 1st, 2018|

Summary of Proposed Telemedicine Policy Changes in Medicare

This is the first of two blogs about the telemedicine provisions in the draft CY2019 Medicare Physician Fee Schedule published last week by the Centers for Medicare & Medicaid Services (CMS). I’ve summarized below what CMS is proposing, and I will follow up with some thoughts about the implications for telehealth coverage and adoption.

Each year, the Physician Fee Schedule addresses telemedicine. The annual rulemaking process is the mechanism by which CMS adds codes to the list of “telehealth services” allowed in Medicare, and also determines what is allowable for remote care.

But this year’s rule was different. It went beyond routine coding changes and clearly showed that CMS is committed to bringing virtual care to seniors. CMS used incredible creativity to get around some very restrictive statutory provisions. CMS Administrator Seema Verma expressed her commitment to telehealth early in her tenure, and this rule shows she was serious.

Telemedicine is generally divided into three modalities: real-time (live video or phone); remote patient monitoring (asynchronous monitoring); and store-and-forward (sending images via secure messaging). All are regulated differently, and this proposed rule addressed all three.

Physician-Patient Telehealth in Medicare
The CMS proposal getting the most attention is the addition of a new code for a “brief communications technology-based service,” or a virtual check-in (real-time) conducted by a physician or other qualified health care professional for 5-10 minutes of medical discussion. It’s meant to allow the provider “to assess whether the patient’s condition necessitates an office visit.” It can’t originate from a provider service offered within the previous seven days nor lead to a service or procedure within the next 24 hours or soonest available appointment. If either of those things is linked to the virtual visit, the virtual check-in gets bundled into the office visit and is not separately billable.

CMS is proposing to price this service at a rate lower than existing E/M in-person visits ($14 for the new service, compared to $92 for an in-person E/M visit) to reflect the “low work time and intensity.” This service could only be furnished to established patients.

The way the Medicare statute is written necessitated the creation of this new code because rural and site limitations apply to primary care and behavioral health codes that would be useful in treating Medicare patients remotely. By creating a new code, CMS got around the statutory limitation. They did as much as they can without Congressional action, but even with their clever approach we need Congress to change the law to fully allow real-time telehealth to take hold in Medicare (as will be discussed in more detail in my second post).

Remote Patient Monitoring
Remote patient monitoring, or the transmission of biometric information from patient to a medical provider asynchronously, is not considered “telehealth” under the Medicare statute. Therefore, it is not restricted by the same limitation applied to real-time telehealth visits. The newly created CPT codes related to remote patient monitoring – 990X0, 990X1, 93XX1 and 994X9 – were deemed by CMS to be “inherently non face-to-face” and therefore not telehealth services. So, these codes will simply be adopted as part of regular Medicare services under Part B in addition to CPT code 99091 which was unbundled from chronic care management (CCM) codes last year This is excellent news for patients with chronic illness who can benefit from a medical provider monitoring their disease state.

Remote Evaluation of Pre-Recorded Patient Information (“Store and Forward”)
Currently, store and forward, sending pre-recorded video or image technology to another provider for evaluation, is not permitted beyond Alaska and Hawaii. Like the virtual check-ins, CMS intends for store and forward information to be used to determine whether or not an office visit is warranted. It is mostly used in dermatology, radiology, pathology and ophthalmology.

CMS proposes to create a new code that would be separately billable as long as the review of a patient-submitted image or video does not result in an in-person office visit with the same physician, or originate from a service provided within the previous seven days by the same physician. In those cases, payment would be considered bundled into the in-person office visit.

CMS is seeking comment as to whether store and forward services should be limited to established patients, or whether there are certain cases where it might be appropriate for a new patient to receive these services.

Payment for Phone/Internet “Interprofessional Consultation”
CMS proposes to make a separate payment for interprofessional consultations undertaken “for the benefit of treating a patient that will contribute to payment accuracy for primary care and care management services.”

Interprofessional consultations include “assessment and management services conducted through telephone, internet, or electronic health record consultations furnished when a patient’s treating physician or other qualified healthcare professional requests the opinion and/or treatment advice of a consulting physician or qualified health professional with specific specialty expertise.”

Eventual Cuts to Base Rate to Achieve Budget Neutrality
CMS estimates that the usage of these new services will result in fewer than 1 million visits in the first year but will eventually result in more than 19 million visits per year, ultimately increasing payments under the PFS by about 0.2 percent. In order to maintain budget neutrality in setting proposed rates for CY19, CMS assumed the number of services that would result in a 0.2 percent reduction in the proposed base rate conversion factor.

Stay tuned for the second part of this series next week.

July 17th, 2018|

CMS Telemedicine Expansion Could Lead to Cuts in Medicare Base Rate

Politico | July 16, 2018

Excerpt:

The rule won’t open the floodgates for telemedicine reimbursement by Medicare. It requires doctors to have a prior relationship with the patient, a limitation criticized by Krista Drobac, executive director of the Alliance for Connected Care. She noted that all states — and the AMA — allow relationships to be established via telemedicine.

“An established relationship with a provider will limit access for people who don’t have a usual source of care, or whose usual medical provider does not offer telemedicine,” Drobac said.

Read Here

July 17th, 2018|

Telehealth Advocates Respond to CMS ‘Virtual Visit’ Proposal

Healthcare Informatics | July 16, 2018

Excerpt:

The CMS proposal brought a mix of enthusiasm and concerns from groups advocating for greater usage of telehealth. “What they have done is creative and brilliant, and it goes further than CMS has ever gone previously to ensure that seniors have services everyone else in the marketplace has,” said Krista Drobac, executive director of the Alliance for Connected Care. On the other hand, she expressed concern that CMS paying for brief e-visits is going to create an environment where providers are going to weigh whether it is worth it to invest in telehealth systems. “What they will probably find is that the reimbursement is not enough to transform their practice and make telehealth part of their work flow,” she said.

Drobac believes CMS has gone as far as it can go within the existing law. She said Congress needs to give the Secretary the authority to waive the telehealth restrictions on all provider codes.

Read Here

July 17th, 2018|

Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry

Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry

Background:

Guidelines strongly recommend patients with heart failure with reduced ejection fraction (HFrEF) be treated with multiple medications proven to improve clinical outcomes, as tolerated. The degree to which gaps in medication use and dosing persist in contemporary outpatient practice is unclear.

Objectives:

This study sought to characterize patterns and factors associated with use and dose of HFrEF medications in current practice.

Methods:

The CHAMP-HF (Change the Management of Patients with Heart Failure) registry included outpatients in the United States with chronic HFrEF receiving at least 1 oral medication for management of HF. Patients were characterized by baseline use and dose of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), angiotensin receptor neprilysin inhibitor (ARNI), beta-blocker, and mineralocorticoid receptor antagonist (MRA). Patient-level factors associated with medication use were examined.

Results:

Overall, 3,518 patients from 150 primary care and cardiology practices were included. Mean age was 66 ± 13 years, 29% were female, and mean EF was 29 ± 8%. Among eligible patients, 27%, 33%, and 67% were not prescribed ACEI/ARB/ARNI, beta-blocker, and MRA therapy, respectively. When medications were prescribed, few patients were receiving target doses of ACEI/ARB (17%), ARNI (14%), and beta-blocker (28%), whereas most patients were receiving target doses of MRA therapy (77%). Among patients eligible for all classes of medication, 1% were simultaneously receiving target doses of ACE/ARB/ARNI, beta-blocker, and MRA. In adjusted models, older age, lower blood pressure, more severe functional class, renal insufficiency, and recent HF hospitalization generally favored lower medication utilization or dose. Social and economic characteristics were not independently associated with medication use or dose.

Conclusions:

In this contemporary outpatient HFrEF registry, significant gaps in use and dose of guideline-directed medical therapy remain. Multiple clinical factors were associated with medication use and dose prescribed. Strategies to improve guideline-directed use of HFrEF medications remain urgently needed, and these findings may inform targeted approaches to optimize outpatient medical therapy.

July 16th, 2018|

Why Congress’s Opioid Effort is a Major Step Forward for Telehealth Reimbursement

Over the past several weeks, the House of Representatives passed 58 opioid-related bills. The Senate is in the midst of considering their own legislation. The intent of congressional leaders in both chambers is to reconcile these legislative packages and send a final bill to the President this year. This effort is key to solving a major national problem and demonstrates that Congress can come together to support people, families and communities in need.

It also happens to be a significant step for Medicare reimbursement of telehealth. Telehealth supporters have long tried to overturn outdated statutory language that requires Medicare beneficiaries who are enrolled in traditional fee-for-service (FFS) to be in specific institutional sites in rural areas for their providers to qualify for Medicare coverage. About 80 percent of Medicare beneficiaries live in 1,200 metropolitan counties that are not considered “rural” under HHS’ definition, and making people go to a clinic or hospital to receive telehealth services defeats the purpose of the technology.

Our challenge as advocates has been assumptions by the Congressional Budget Office (CBO) that increasing access to telehealth for seniors will increase utilization without a subsequent decrease in utilization of other forms of care. In other words, they think people will use telehealth and also go to the doctor in person, thereby increasing costs. Studies showing that telehealth substitutes for in-person care, reduces re-admissions and increases preventive care have not convinced them, nor have the major investments that capitated insurers have made in telehealth services.

The opioid effort in Congress has changed the course of this debate. As a result of the dire need for behavioral health services to help mitigate the crisis, both the House and Senate have moved bills to lift telehealth restrictions in Medicare to enable more mental health and substance abuse providers to see patients via telehealth, and thereby expand access to care. The eTREAT Act (S. 2901) in the Senate would entirely lift Medicare’s originating site restrictions on reimbursement for patients suffering from substance use disorder (SUD). The Access to Telehealth Services for Opioid Disorders Act (H.R. 5603) in the House would give the Secretary of HHS authority to waive telehealth restrictions for opioid abuse disorder.

These bills, led by a powerful group of bipartisan lawmakers, have cracked the CBO code. They demonstrate what telehealth advocates have been trying for years to convey – allowing telehealth coverage in Medicare will not significantly impact the federal budget. According to CBO, the House version would cost a mere $11 million over 10 years. The Senate bill, which entirely lifts the restrictions, is only $14 million. That’s out of a program that will spend as much as $10 trillion over the same time period.

The relatively small price tag and bi-partisan support of these bills sets the stage for Congress to consider future legislation that would remove even more barriers to telehealth, and could pave the way for originating site restrictions to be lifted for all patients. In the meantime, Medicare patients with substance abuse disorders will be able to access care remotely. This is a huge step forward.

June 27th, 2018|

The impact of telehealth remote patient monitoring on glycemic control in type 2 diabetes: a systematic review and meta-analysis of systematic reviews of randomised controlled trials

BMC Health Serv Res: The impact of telehealth remote patient monitoring on glycemic control in type 2 diabetes: a systematic review and meta-analysis of systematic reviews of randomised controlled trials

Background: There is a growing body of evidence to support the use of telehealth in monitoring HbA1c levels in people living with type 2 diabetes. However, the overall magnitude of effect is yet unclear due to variable results reported in existing systematic reviews. The objective of this study is to conduct a systematic review and meta-analysis of systematic reviews of randomised controlled trials to create an evidence-base for the effectiveness of telehealth interventions on glycemic control in adults with type 2 diabetes.

Methods: Electronic databases including The Cochrane Library, MEDLINE, EMBASE, HMIC, and PsychINFO were searched to identify relevant systematic reviews published between 1990 and April 2016, supplemented by references search from the relevant reviews. Two independent reviewers selected and reviewed the eligible studies. Of the 3279 references retrieved, 4 systematic reviews reporting in total 29 unique studies relevant to our review were included. Both conventional pairwise meta-analyses and network meta-analyses were performed.

Results: Evidence from pooling four systematic reviews found that telehealth interventions produced a small but significant improvement in HbA1c levels compared with usual care (MD: -0.55, 95% CI: -0.73 to – 0.36). The greatest effect was seen in telephone-delivered interventions, followed by Internet blood glucose monitoring system interventions and lastly interventions involving automatic transmission of SMBG using a mobile phone or a telehealth unit.

Conclusion: Current evidence suggests that telehealth is effective in controlling HbA1c levels in people living with type 2 diabetes. However there is need for better quality primary studies as well as systematic reviews of RCTs in order to confidently conclude on the impact of telehealth on glycemic control in type 2 diabetes.

June 26th, 2018|

Letter to Chair Hatch and Ranking Member Wyden, Senate Finance Committee

Download PDF
May 23rd, 2018|

Letter to Ms. Seema Verma, Administrator, Centers for Medicare and Medicaid Services

Download PDF
March 5th, 2018|
Go to Top